Get started

Healthcare

BLRX-BREAKOUT-UPDATEBLRX had a strong rally today and it's just getting started. In the related idea my price target was $1.34. Today's high was $1.78 Check out the weekly chart: Photo Finish. $1.34 was 1.618 extension level from Waves 1 & 2. Since the price-action broke $1.34 we will have an extended 3rd wave. I expect a very strong rally tomorrow, I will update in the morning before the open to confirm. Target is hard to predict since its impossible to know what level extending waves will terminate. I will keep a close eye on the price-action. Will update. -AB
NASDAQ:BLRXLong
by FibMarketWatch
ANAB - "ANAB-tomy" Of A Winning Long Trade?Sorry for the stuffy nose! Nonetheless, here I talk about qualities of a trade that help determine it as a winner. This is just a short version of what to look for, just to give some of the things to consider in the process. As a general statement, there are 2 things that make up a stock: technical factors (price behavior) & fundamental factors (financial statement info). Fundamentals are important for longterm investments where company growth & strength are important, since over time, more people will get interested and buy the stock in the future for further price appreciation (5-10+ years for a solid investment). Simple fundamentals just looks at company profits and how much cash the company has access to, but for a detailed fundamental analysis, the company will need to be known and understood on a very high level as if the investor is one of he founders of the company. Before the investment is made, you must know almost everything about how goods/services reach the consumer/customer. For a trader, correct technical analysis is most important (everyone can do technical analysis, but it takes time to do it in a more realistic fashion without dreaming too much or trying too hard to predict a specific future price action). The more factors that favor your objective to buy the stock, whether as a trade or investment, the more likely you will win from the trade. Here is the list from the video: 1. Technical favor -Price accumulation: price usually builds up slowly before exploding upward in an uptrend, with only few/small price corrections in the trend (it is hard to see this early but it is typically only obvious late AFTER the trend has started) -Volatility contraction-expansion: I talk about this all the time I'll skip it; it is very important to always look for though -Price eagerness to increase: when price keeps trying to push upward to newer levels, this tells that at least there are also other people who see the stock going higher and are willing to put their money on the line for it -Supportive base: the price action should show you that the price has no interest in testing lower levels, which means there are no aggressive sellers, investors or other traders are not selling off and there is a positive sentiment toward the stock -Industry/Sector performance: this was not included in the video, but it usually gives you a great technical context especially when you are diversifying or trying to pick a home run stock (it's still very difficult to pick one though) 2. Fundamental favor (if considering longterm investing) -EPS growth past 3-5yrs (should mirror revenue/net income): this tells you the company's plan to grow/expand and make profit in the process is working, and hence the company is still appealing to old and newer investors -Free cash flow: I didn't explain this well in the video, but I meant to say that a good cash flow means the company has cash on hand aside from other assets to be able to pay off any debt or sudden expenses today if the need arises (this is a very simplified version just to give you an idea) Let's see what ANAB can do! Looking forward to comments or PM discussions.
NASDAQ:ANABEducation
by themdtrader
ENDP - SHORT-TERM SHORT & LONG-TERM BUY - Endo Pharma ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. The Crash: Revenue Is In Free Fall Endo Pharmaceuticals: The Free Fall Continues Mar. 26, 2018 Summary Revenue from ENDP's core Generics business is in decline and other business segments appear in disarray. Its $8B debt load is at 7.5x run-rate EBITDA. If operating income continues to slide, it could hurt ENDP's ability to service its debt. ENDP ENDP trades at 9x EBITDA, but it is uncertain if potential legal exposures pursuant to opioids are priced in. Sell ENDP. This idea was discussed in more depth with members of my private investing community, Shocking The Street. There is a war being fought over drug prices. Lawmakers have hit back at price gougers and opioid manufacturers, and Endo Pharmaceuticals (ENDP) is in the middle of it. A few months ago, I thought Endo was at an inflection point and there was a good probability it could turn things around. However, its slide continues. What: The bottom dropped out from under shares of Endo International plc (NASDAQ:ENDP), the specialty pharma famous for selling "uncrushable" opioids and agreeing to enormous legal settlements. After management revealed disturbing revisions of its 2016 full-year estimates, the stock plummeted 41.4% last month, according to data from S&P Global Market Intelligence. Logical? Sold because they sell opiates? Are opiated still needed/critical to US Healthcare? NO! BIG Consolidation period: 4 Years (2014-2018) The First CYCLE WAVE Completed. Now, in the middle of the SECOND WAVE (Correction) Key Levels for Retrace: 1, 1.382, & 1.618 Look for retrace back to around $13.00 ENDP screenshots.firefox.com screenshots.firefox.com screenshots.firefox.com Most Recent News: Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Analysts at RBC Capital upgraded Endo International PLC (NASDAQ:ENDP) from Sector Perform to Outperform. Endo shares rose 2.56 percent to $16.05 in pre-market trading. Will update. -Stay humble America, -AB
ELong
by FibMarketWatch
Biogen Earnings Swing July 2018Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was certainly reason for bullish sentiment, it ran too far too fast and indicators pointed towards to a sell off. I thus opened put options on July 9, expiring July 13 2018 (currently in the money). We are now only about two weeks away from Biogen's earning report. After studying historical data and charts, I've found that there is often a sell off prior to earnings OR there is a run up then a slight sell off right before the earnings date. I've annotated the chart with periods that indicate this. In this case, I believe downward momentum will continue followed by a slight rally pre-earnings then a sell off. Opening JUL20 puts may be a smart move at this time. In the long term, Biogen -0.21% is very scalable and overall is very promising. I agree with Citi's PT of 371. www.wsj.com
NASDAQ:BIIBShort
by UnknownUnicorn2997486
ASX:PGC Paragon Healthcare - waiting for a good entry pointASX:PGC Paragon Healthcare seems to be gaining traction and has a slight pull back recently but I would still wait for a clearer signal to enter. A nice cup and handle has been formed and i am waiting for the RSI to cross the 50 mark with conviction before entering. That will also mean I prefer to enter after the prices cross back into the main channel at $0.855 at least. It might be proven to be a little late in future but a stronger signal to enter is still a safer bet. If you decide to enter now, set your stop loss tight at $0.795 or $0.765 depending on your risk appetite. Target set at between $0.96 to $1.045 (ATH). A break below $0.765 will invalidate this view.
ASX:PGC
by paper_value
GlaxoSmithKline ShortShort from $42.01. - Market Cap: $102B - Beta: 0.83 - P/B: 20.42 - GSK’s consumer healthcare segment sales were down in 2017 due to a slowdown in global growth of its key consumer categories. - They have also faced pricing pressure from competition and slow down in emerging markets. Although GSK have several candidates in different stages of development, the company has been set back on numerous occasions by the regulators. The largest setbacks in the past few quarters include the phase 3 data on chronic coronary heart disease, Duchenne muscular dystrophy candidate, kydrisa failing to meet the primary end point in a phase 3 study. - The company phases massive competition from small start-ups to large pharmaceutical corporations. There consumer healthcare segment faces competition from big companies like Johnson & Johnson, Colgate Palmolive, Procter & Gamble and Pfizer. - Advair, one of GSK’s largest revenue providers is facing intense competition in the asthma and COPD market from AstraZeneca and Merck respiratory drugs. NeroTree Capital rates GlaxoSmithKline PLC as a SELL with a price target of $38.
NYSE:GSKShort
by UnknownUnicorn2415222
1
SGYP Is Setting Up for A Big Move!SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation), which is the 0.382 retracement level of 17's highs and the 1.618 retracement level of this year's highs.
SLong
by ArthaVidya
1
Fitbit: an AI and IoT Play - This is the Cheapest it's Gonna GetFitbit's value isn't just in its wearables. It's in its data and cloud connectivity. Fitbit's had a good run with its line of functional, stylish activity trackers and health monitors. Customers can choose between classic trackers, a few smart watches, and even smart headphones and weight scales - with a large selection of accessories to mix and match throughout the product line. But that's only taken Fitbit so far - in the case of its stock price, down massively into the single digits since 2016. Fitbit's stock has been adrift in the single-digit doldrums for a long time now. But believe it or not. . . This is the cheapest Fitbit is ever going to get. Why? Because Fitbit is making its foray into its next big space, its next supreme endeavor - health monitoring, big data, electronic medical records, and cloud connectivity. On 4/30/18 Fitbit announced it is partnering with Google's Cloud Platform to facilitate its entry into the data and I.o.T (Internet of Things) of healthcare. Real-time biometrics, new and innovative application use and creation, population health analysis, and more will form the meat-and-potatoes of Fitbit Health Solutions - Fitbit's initiative to use omnipresent real-time and stored data and analysis to achieve positive health outcomes with mass health monitoring. Visionaries and forward-thinkers have been talking about the burgeoning field of biometric sensors and health monitoring for a few years now. Fitbit and Google look to be the mainstream facilitators and operators in this new space of healthcare. And we all know humanity's two concurrent life-changing revolutions - AI and blockchain - will be a big part of this. The technicals are nicely supporting the story. The stock has been in the $5-$6 USD range throughout 2018, and a case could be made for an inverse head-and-shoulders bottom printing since February 2018 to today (though it might be just range noise); but with volume relatively low, we may only just now be at an inflection point - the big moves and big money are probably a little ways out as Fitbit's brand-new endeavors prove themselves throughout the rest of the year and into the next and beyond. Fitbit could be at a massive discount with huge money to be made longer-term. Please like, follow, and share, and maybe we can have fun and do great things together. Thanks again! See it on the site: holsturr.com/category/markets/charts/ ** For speculative and research purposes only - good luck! **
FLong
by holsturr
1
MRK - Too Good To Be True?The price here has focused into the obvious descending triangle for almost about a year now! It is not obvious if it will hold or not, but the current company health especially regarding profitability along with price action point towards a downward move, especially after the bullish momentum over the last couple of days. This play is being taken to play on the chance that the stock continues to retrace some of its gains from the past week, ideally before the next earnings report. Let's see how it goes down; it should be a very short-term trade. Stop @ 60.13 Target @ 57.09
NYSE:MRKShort
by themdtrader
2
UNH - Slowing Down or Beginning of The End?This stock has been one of the best winners in healthcare over the past few years, in terms of company health, profitability and correlation to stock price action. All the same, just like with A , the current market uncertainty has left the stock here in a wedge pattern after its earnings report. Even though the earnings beat estimates, it was not better than the prior growth experienced and so combined with the overbought nature of the stock, this could be a sign that the stock is topping out at least for now. In short, if the company fails to keep growing, fear could set in and investors will go ahead to ease off the gas pedal, leading to a possible bearish trend. For now, I am looking for a bearish drift after earnings, but I look to stay longer if a bearish trend develops; losses will be cut quickly. Stop @ 242.18 Target @ 227.79
NYSE:UNHShort
by themdtrader
PG.... Sad Story but meeting support? I don't follow this stock and it was a friend of mine who pointed it out to me. There is a massive amount of pain in this stock chart. First off, you had a bad, bad break of the 200 day moving average all the way back on January 23rd. If you were watching the charts, this should have been a pretty good signal that something was up with the stock. You also had above average volume coming in confirming that this move was most likely meaningful. The second warning shot was the death cross that happened on February 8th. Today's bloodbath on top of the recent months of selling has taken this puppy all the way back to the levels it was at in January 2016. Ouch If you take this all the way back to 2009 and draw a best fit line, today's prices stopped to meet this trendline support. I would have to hope that the pain is in the past for PG and maybe this is a capitulation "wash out." If it breaks this line.... then "adios amigo." How far it goes, how long it lasts.... nobody knows.
NYSE:PG
by themuzzman
SEVERAL BULLISH SIGNS FOR CHEAP HEALTHCARE STOCKFound myself looking around for some side plays with the stock markets rallying today all while cryptos are facing some uncertainty. I'm also keeping my fingers crossed for UofL to sign Chris Mack as their head men's basketball coach. Anywho lets get into it TRXC TransEnterix is a small healthcare instrument supply company, the fundamentals are not great but its starting to show some great signs, with it appearing to be - breaking out of a down trend from October - printing a cup and handle formation since February - breaking out of a smaller descending wedge for March - SMA 20 crossed above the SMA 50 Given all the factors I'm hoping we can gather support through the .23 retracement and eventually work its way back to the .618 Overall this seems like a cheap play and could be fun to watch over the coming weeks. Not advice - happy Monday *Delgado*
TLong
by aledelga